Case Report

Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab

Table 1

Adverse Drug Reaction Probability Scale.

QuestionYesNoDo not knowIbrutinibCetuximab

1. Are there previous conclusive reports on this reaction?+10011
2. Did the adverse event appear after the suspected drug was administered?+2-1022
3. Did the adverse event improve when the drug was discontinued or a specific antagonist was administered?+10010
4. Did the adverse event reappear when the drug was readministered?+2-102-1
5. Are there alternative causes that could on their own have caused the reaction?-1+20-1-1
6. Did the reaction reappear when a placebo was given?-1+1000
7. Was the drug detected in blood or other fluids in concentrations known to be toxic?+10000
8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased?+10011
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure?+10000
10. Was the adverse event confirmed by any objective evidence?+10011
Total73